RFA
IMMU

Reilly Financial Advisors’s Immunomedics Inc IMMU Stock Holding History

Reilly Financial Advisors’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-460
Closed -$6K – 955
2019
Q3 		$6K Buy
+460
New +$6.76K ﹤0.01% 734

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Reilly Financial Advisors's IMMU Position: Q4 2019 in Review

Reilly Financial Advisors sold out of Immunomedics Inc (IMMU) in Q4 2019, closing a stake of 460 shares — an estimated $6K sold.

Reilly Financial Advisors first reported a position in IMMU in Q3 2019 and held it in 1 quarter. The position peaked at $6K in Q3 2019. 245 funds tracked by Wall St. Rank hold IMMU as of Q4 2019.

  • Reilly Financial Advisors reported no remaining Immunomedics Inc position as of Q4 2019 after selling out during the quarter.
  • Reilly Financial Advisors sold 460 Immunomedics Inc shares in Q4 2019, an estimated $6K.
  • Reilly Financial Advisors first reported a position in Immunomedics Inc in Q3 2019 and held it in 1 quarter.
  • Reilly Financial Advisors's Immunomedics Inc position peaked at $6K in Q3 2019.
  • 245 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2019.

Based on Reilly Financial Advisors's 13F filing for Q4 2019, filed 16 Jan 2020.